Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:08 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease
NCT01150890 · Amgen · PHASE2 · terminated · last registry update 2022-01-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated early based on an imbalance in worsening Crohn's disease in active treatment groups” | – | Registry record, Amgen |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL17RA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-09-21Also stopped (terminated): Amgen, Placebo + Brodalumab (NCT01902290)
- 2022-02-28Results posted on the registry: Amgen, Placebo + Brodalumab (NCT01902290)
- 2022-02-28Results posted on the registry: Amgen, AMG 827 (NCT01059448)
- 2022-02-28Also stopped (terminated): Amgen, AMG 827 (NCT01059448)
- 2021-12-28Results posted on the registry: Amgen, Brodalumab (NCT01199302)
- 2021-12-28Also stopped (terminated): Amgen, Brodalumab (NCT01199302)
- 2021-12-21Results posted on the registry: Amgen, Brodalumab + Placebo (NCT00950989)
- 2021-11-26Results posted on the registry: Amgen, AMG 827 + Placebo (NCT01199289)
- 2021-11-26Results posted on the registry: Amgen, Brodalumab (NCT00771030)
- 2021-09-30Also stopped (withdrawn): Kyowa Kirin Co., Ltd., KHK4827-Active + KHK4827-Placebo (NCT04614298)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision